Rania S Abdel Aziz, Enas M Radwan, Abdelhamid M Fouad, Mona S Abdellateif, Sally Elfishawi
{"title":"急性髓系白血病患者骨髓中转录因子SOX11表达的临床意义","authors":"Rania S Abdel Aziz, Enas M Radwan, Abdelhamid M Fouad, Mona S Abdellateif, Sally Elfishawi","doi":"10.5306/wjco.v16.i6.107271","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The prognosis for acute myeloid leukemia (AML) remains poor, underscoring the need for a deeper understanding of its underlying molecular mechanisms.</p><p><strong>Aim: </strong>To assess the significance of <i>SOX11</i> gene expression in the clinical features, response to treatment, and survival outcomes of adult patients with AML.</p><p><strong>Methods: </strong>This retrospective study enrolled 102 adults with AML. <i>SOX11</i> gene expression in bone marrow samples was measured using real-time PCR. Data were correlated to the patients' clinical features, response to treatment, and survival rates.</p><p><strong>Results: </strong>Increased <i>SOX11</i> expression was significantly associated with the presence of the <i>FLT3-ITD</i> mutation (<i>P</i> < 0.001), the FAB-M2 subtype (<i>P</i> = 0.008), and cytogenetic abnormalities (<i>P</i> = 0.011). However, no significant association was found between SOX11 expression and other clinical laboratory parameters, complete remission, disease-free survival, or overall survival.</p><p><strong>Conclusion: </strong><i>SOX11</i> expression may serve as a marker to identify specific subsets of AML patients who could benefit from intensive targeted chemotherapy.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 6","pages":"107271"},"PeriodicalIF":3.2000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198852/pdf/","citationCount":"0","resultStr":"{\"title\":\"Clinical significance of the transcription factor (SOX11) expression in the bone marrow of acute myeloid leukemia patients.\",\"authors\":\"Rania S Abdel Aziz, Enas M Radwan, Abdelhamid M Fouad, Mona S Abdellateif, Sally Elfishawi\",\"doi\":\"10.5306/wjco.v16.i6.107271\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The prognosis for acute myeloid leukemia (AML) remains poor, underscoring the need for a deeper understanding of its underlying molecular mechanisms.</p><p><strong>Aim: </strong>To assess the significance of <i>SOX11</i> gene expression in the clinical features, response to treatment, and survival outcomes of adult patients with AML.</p><p><strong>Methods: </strong>This retrospective study enrolled 102 adults with AML. <i>SOX11</i> gene expression in bone marrow samples was measured using real-time PCR. Data were correlated to the patients' clinical features, response to treatment, and survival rates.</p><p><strong>Results: </strong>Increased <i>SOX11</i> expression was significantly associated with the presence of the <i>FLT3-ITD</i> mutation (<i>P</i> < 0.001), the FAB-M2 subtype (<i>P</i> = 0.008), and cytogenetic abnormalities (<i>P</i> = 0.011). However, no significant association was found between SOX11 expression and other clinical laboratory parameters, complete remission, disease-free survival, or overall survival.</p><p><strong>Conclusion: </strong><i>SOX11</i> expression may serve as a marker to identify specific subsets of AML patients who could benefit from intensive targeted chemotherapy.</p>\",\"PeriodicalId\":23802,\"journal\":{\"name\":\"World journal of clinical oncology\",\"volume\":\"16 6\",\"pages\":\"107271\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-06-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198852/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World journal of clinical oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5306/wjco.v16.i6.107271\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v16.i6.107271","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Clinical significance of the transcription factor (SOX11) expression in the bone marrow of acute myeloid leukemia patients.
Background: The prognosis for acute myeloid leukemia (AML) remains poor, underscoring the need for a deeper understanding of its underlying molecular mechanisms.
Aim: To assess the significance of SOX11 gene expression in the clinical features, response to treatment, and survival outcomes of adult patients with AML.
Methods: This retrospective study enrolled 102 adults with AML. SOX11 gene expression in bone marrow samples was measured using real-time PCR. Data were correlated to the patients' clinical features, response to treatment, and survival rates.
Results: Increased SOX11 expression was significantly associated with the presence of the FLT3-ITD mutation (P < 0.001), the FAB-M2 subtype (P = 0.008), and cytogenetic abnormalities (P = 0.011). However, no significant association was found between SOX11 expression and other clinical laboratory parameters, complete remission, disease-free survival, or overall survival.
Conclusion: SOX11 expression may serve as a marker to identify specific subsets of AML patients who could benefit from intensive targeted chemotherapy.
期刊介绍：
The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
